RN 1101
Alternative Names: RN-1101Latest Information Update: 26 May 2025
At a glance
- Originator Rui Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 20 May 2025 Rui Therapeutics plans a phase 0 trial for Haematological malignancies (Second-line therapy or greater) (IV, Infusion) in May 2025 (NCT06976437)
- 16 May 2025 Preclinical trials in Haematological malignancies in China (IV) before May 2025